Volume 11, Issue 3 (Scientific Journal of Hamadan University of Medical Sciences-Autumn 2004)                   Avicenna J Clin Med 2004, 11(3): 5-11 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Salek R, Ghavam Nasiri M R. Evaluation of the Osteosarcoma Chemotherapy Regimens and its Treatment Results in Meshed Omid Hospital. Avicenna J Clin Med 2004; 11 (3) :5-11
URL: http://sjh.umsha.ac.ir/article-1-597-en.html
Abstract:   (6886 Views)

This study was designed to evaluate results of neoadjuvant and adjuvant chemotherapy for nonmetastatic osteosarcoma patients. Forty four patients who were referred to Omid hospital from 1994 to 1999 were eligible to the study.

For comparison based on different chemotherapy regimens which had been prescribed, all patients were classified into 3 different subgroups named as HDMTX (including high dose methotrexate and other drugs based on a protocol known as T10), 3 drugs (low dose methotrexate, vincristine and cyclophosphamide) and 4 drugs (low to intermediate dose
   methotrexate, vincristine, cyclophosphamide and adriamycine) regimens.

While 2 and 5 years Relapse Free Survival (RFS) were 45% and 28%  respectively, there was not any significant statistical difference between the groups. In addition Median Event Free Survival (MEFS) was 18.5 months and again there was not any significant statistical difference between groups (15.5 months for HDMTX, 21 months for 3 drugs and 24 months for 4 drugs
   regimens). Considering as a prognostic factor, effects of adriamycin prescription, neoadjuvant chemotherapy and adequacy of chemotherapy courses in MEFS were evaluated. Putting Adriamycin into regimen and adequacy of chemotherapy courses had a significant effect on MEFS improvement but neoajuvant chemotherapy didn’t have such a significant effect.

As methotrexate was integrated into all different regimen however with different doses the study didn’t show improving MEFS with increasing doses of this drug.

Full-Text [PDF 352 kb]   (4979 Downloads)    
Type of Study: Original | Subject: Other Clinical Specialties

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Avicenna Journal of Clinical Medicine

Designed & Developed by : Yektaweb